<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04155996</url>
  </required_header>
  <id_info>
    <org_study_id>VTC-MLS-EC01</org_study_id>
    <nct_id>NCT04155996</nct_id>
  </id_info>
  <brief_title>Data Acquisition Study in Inadequately Balanced Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Data Acquisition Study in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Balanced With Oral Antidiabetic Agents and Basal Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ValoTec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>APHP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ValoTec</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to collect continuous glucose monitoring (CGM) data, coupled with
      physical activity and everyday day life data. The purpose of this data collection is to help
      diabetologists to make recommendations to optimize type 2 diabetic patient management.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Data collection - Blood glucose levels</measure>
    <time_frame>28 days</time_frame>
    <description>Patients wear a continuous glucose monitoring patch and record blood glucose level measurements (in mg/dl) over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Data collection - Number of steps</measure>
    <time_frame>28 days</time_frame>
    <description>Patients wear an activity tracker that will record their number of steps over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Data collection - Sleep hours</measure>
    <time_frame>28 days</time_frame>
    <description>Patients wear an activity tracker that will record their sleep hours (sleep start time and sleep end time) during nighttime.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Data collection - Daily meals information</measure>
    <time_frame>28 days</time_frame>
    <description>Patients manually record information about meals in a dedicated smartphone application.
Each meal size (Small, Medium or Large) and glycemic index (Low, Medium or High) is evaluated by patients in the application.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Data collection - Physical activity information</measure>
    <time_frame>28 days</time_frame>
    <description>Patients manually record information about physical activities in a dedicated smartphone application.
Each physical activity duration (Short, Medium or Long) and intensity (Low, Medium or High) is evaluated by patients in the application.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Data collection - Medical treatment information</measure>
    <time_frame>28 days</time_frame>
    <description>Patients manually record information their medical treatment in a dedicated smartphone application.
Treatment intake times are recorded in the smartphone application.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>data collection</arm_group_label>
    <description>20 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>data collection</intervention_name>
    <description>Patients will receive a full data acquisition set with CGM sensors, an activity tracker and a smartphone application in which they can log daily events.</description>
    <arm_group_label>data collection</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 Diabetic patients followed by french primary care or specialized centers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetic patient (T2D) with HbA1c ≥ 8% in the month prior to inclusion

          -  Patient is treated with oral anti-diabetics and / or analogous combined with basal
             insulin therapy (1 injection of slow-acting insulin in the evening)

          -  Age ≥ 35 years

          -  Diabetes diagnosis done over 1 year ago

          -  Patient accepting for 2 periods of 14 days spaced at most 3 days to wear a Freestyle
             glucose meter, a bracelet for measuring physical activity and to log daily life events
             in a dedicated smartphone application

          -  Patient is able to use a smartphone

          -  Patient is affiliated to the French health insurance system

        Exclusion Criteria:

          -  Patient has Type 1 diabetes, diabetes secondary to pancreatic pathology,
             endocrinopathy or iatrogenic diabetes

          -  Patient is treated with a rapid-acting insulin

          -  Patient has had a severe hypoglycaemia in the year preceding inclusion

          -  Patent has a severe renal insufficiency (defined by a Glomerular Filtration Rate below
             30 ml/min)

          -  Patient has had a myocardial infarction or other life-threatening medical condition in
             the last 6 months

          -  Patient has cognitive disorders or evolutionary psychiatric pathology

          -  Pregnant woman or woman likely to be pregnant, breastfeeding woman

          -  Patient plans to travel outside europe during the study

          -  Patient is participating to another clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marine HALBRON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary TENDON</last_name>
    <phone>+33141659140</phone>
    <email>clinique@valotec.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Christophe LOURME, Pr</last_name>
    <phone>+33141654355</phone>
    <email>jc.lourme@valotec.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GH Pitié Salpêtrière Charles Foix</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marine Halbron, PH</last_name>
      <phone>+33142178263</phone>
      <email>marine.halbron@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

